Fichna J, Mazur M, Grzywacz D, Kamysz W, Perlikowska R, Piekielna J, Sobczak M, Sałaga M, Toth G, Janecka A, Chen C, Olczak J. Novel glycosylated endomorphin-2 analog produces potent centrally-mediated antinociception in mice after peripheral administration.
Bioorg Med Chem Lett 2013;
23:6673-6. [PMID:
24220171 DOI:
10.1016/j.bmcl.2013.10.041]
[Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 10/19/2013] [Accepted: 10/22/2013] [Indexed: 11/20/2022]
Abstract
We report the synthesis and pharmacological characterization of a novel glycosylated analog of a potent and selective endogenous μ-opioid receptor (MOP) agonist, endomorphin-2 (Tyr-Pro-Phe-Phe-NH2, EM-2), obtained by the introduction in position 3 of the tyrosine residue possessing the glucose moiety attached to the phenolic function via a β-glycosidic bond. The improved blood-brain barrier permeability and enhanced antinociceptive effect of the novel glycosylated analog suggest that it may be a promising template for design of potent analgesics. Furthermore, the described methodology may be useful for increasing the bioavailability and delivery of opioid peptides to the CNS.
Collapse